Kornimate/medical-research-clean huggingface dataset:
effects of laughter yoga on hemodialysis patients' plasma-beta endorphin levels, pain levels and sleep quality

Conditions: Laughter Yoga; Hemodialysis Patients

Summary: this study aimed to assess the effectiveness of laughter yoga on hd patients' plasma beta endorphin levels, pain levels and sleep quality.

while there are studies conducted with laughter yoga on different patient groups in turkey, no studies have been found on hemodialysis patients specifically. for this reason, it was thought that studies are needed which will prove the effect of laughter yoga practices on the plasma beta-endorphin levels, pain levels and sleep quality of hemodialysis patients.

Eligibility criteria:
inclusion criteria: * receiving treatment in a dialysis center * must be between 18 and 80 years old and willing to participate in the study * receiving hd treatment at least twice a week for a month or longer * having a pain level and above * level of 5 above according to the pittsburgh sleep quality index. exclusion criteria: * not taking any medicine for sleeping disorder * not having any visual, hearing or communication impairments * not having any mental disorders

Keywords: laughter yoga hemodialysis pain sleep beta endorphin
evaluating the occurrence of participation trends among weight loss clinical trials patients

Conditions: Weight Loss

Summary: clinical studies, with a distinct focus on weight loss, play a crucial role in evaluating the safety and effectiveness of novel treatments. these trials serve as instrumental means to determine whether new medications surpass conventional therapies, providing substantial evidence for their broader adoption. the primary objective is to meticulously scrutinize trial completion rates and voluntary withdrawals within this specific patient group.


Eligibility criteria:
inclusion criteria: * interested in losing weight and not enrolled in a formal weight loss program or taking medications or supplements that may cause weight change * participant must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study. * aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed exclusion criteria: * enrolled in another research study * inability to provide written informed consent * has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial

Keywords: weight loss
efficacy of adding patellar mobilization to hip and knee exercises in patients with patellofemoral pain syndrome

Conditions: Patellofemoral Pain Syndrome

Summary: patellofemoral pain syndrome is a common source of anterior knee pain. the causes of pfps may be multifactorial such as biomechanical disorders, muscle weakness which affect the dynamic stability of lower limb and alter patellar tracking in trochlear groove. moreover, the syndrome associated with muscular tightness of iliotibial band, gastrocnemius, soleus, hamstring and quadriceps. strengthening and stretching exercises are effective in improving patient's symptoms. however, they do not sufficient in correction of kinematic changes associated with pfps. patellar mobilization is effective in improving patient'symptoms in cases with pfps. however, studies that conducted patellar mobilization were either low quality studies or no study combined patellar mobilization with hip and knee exercises. therefore, apta guidelines recommended for conducting high quality study to investigate the effect of adding patellar mobilization to exercise therapy to support the definite recommendation delivered to therapists.

this is interventional study in which patients will receive stretching and strengthening exercises in control group. in addition, experimental group will receive the same exercises of control group in addition to patellar mobilization, retinacula release and deep friction message.

Eligibility criteria:
inclusion criteria: 1. age ranging between 18 and 35 years 2. tenderness of medial and lateral borders of patella 3. retropatellar pain 4. duration of symptoms of patellofemoral pain syndrome is greater than 4 weeks 5. positive patellar compression test 6. pain intensity is more than 3 at visual analogue scale 7. had a history of insidious onset 8. had anterior knee pain during 2 or more of provocative activities that include stair ascent or descent, kneeling, prolonged sitting, or squatting exclusion criteria: 1. previous patellar realignment surgery or patellar fracture 2. had a history of traumatic patellar dislocation 3. had a history of previous knee surgery 4. had any form of inflammatory arthritis that include osteoarthritis or rheumatoid arthritis 5. had a history of knee menisci, ligaments, bursae, or synovial plica syndrome dysfunction 6. taking corticosteroids or nonsteroidal anti-inflammatory medication 7. inability to attend treatment program to the end of sessions

Keywords: patellofemoral pain syndrome strength stretch mobilization release deep friction message retinacula
a multicenter, randomized, open-labeled, cross-over, active-controlled, phase iv clinical trial to evaluate the preference of formulation and the efficacy and safety of renamezin and kremezin in pre-dialysis patients with chronic renal failure

Conditions: Chronic Renal Failure

Summary: a multicenter, randomized, open-labeled, cross-over, active-controlled, phase iv clinical trial to evaluate the preference of formulation and the efficacy and safety of renamezin and kremezin in pre-dialysis patients with chronic renal failure


Eligibility criteria:
inclusion criteria: * pre-dialysis patients with chronic renal failure stage * patient for holding the stable state in serum creatinine 2.0mg/dl - 5.0mg/dl of mdrd gfr 15-60ml/min/1.73m2 for 3 months before screening * patients haven't experienced dose spherical carbon adsorbent for 3months before screening * patients who were no noticeable change for 4weeks before screening and are expected to change is not needed during therapy in the therapy of chronic renal failure(type of blood pressure medication and dose -related, diet therapy) * patients spontaneously written consent to participate in this clinical trial exclusion criteria: * patients with passes through the digestive tract disorders * patients with uncontrolled constipation symptoms * kidney transplant patients * patients who are taking immunosuppressive drugs * patients suffering from digestive tract ulcers and esophageal varices * patients with uncontrolled hypertension * patients hospitalized with cardiovascular disease within 3 months of the screening * patients with current infections * patients who do not fulfill therapies of chronic renal failure (taking medicine and diet) as appropriate * patients with hepatic impairment (2.5 times greater than the upper limit of normal levels of ast, alt) * uncontrolled diabetes (hba1c \> 10 % or a fasting glucose \> 180mg / dl) * patients with malignant tumors (however, if you do not relapse within five years after completion of therapy can be registered) * pregnant women, nursing mothers * those who do not agree to a contraceptive method allowed for the possibility of pregnancy in women * patients participating in another clinical trial in addition to the current clinical trial * subjects with dependency on drugs or alcohol * subjects who took any other investigational drugs within 30 days before participating this clinical trial study * patients expected to starting the dialysis within three months * other patients deemed unsuitable tester
impact of grafts and endografts for abdominal aneurysms on arterial stiffness.

Conditions: Aortic Aneurysm, Abdominal

Summary: the purpose of this study is to evaluate by non-invasive methods the change in central hemodynamics and arterial stiffness produced by grafts and endografts after abdominal aortic aneurysm repair. our main goal is to measure the changes in: augmentation index, central blood pressure, pulse wave analysis, pulse wave velocity.

the measures will be done before the procedure and after them. we will use the device called: sphygmocor (atcor medical, sydney, australia).

Eligibility criteria:
inclusion criteria: * patients with diagnosis of abdominal aortic aneurysm requiring repair (open or endovascular) based on guidelines criteria for management. exclusion criteria: * patients who don´t want to enter in the study. * patients who don´t want to sign the informed consent.

Keywords: arterial stiffness, central hemodynamics
surveillance for early liver injuries caused by zhuanggu guanjie pill

Conditions: Drug-Induced Liver Injury

Summary: this is a prospective registry study to surveil early liver injuries caused by zhuanggu guanjie pill (zggj pill) through a non-intervention observational way. and attempt to establish a predictive model to screen susceptibilities to zggj pill.

the primary objectives of this study include: (i) the detection of patients with serum liver biochemistry abnormalities less than 8 weeks after intake of zggj pill; (ii) the record of overall individuals with demographics, underlying diseases, physical status, medication information, clinical laboratory index, and so on; (iii) the specimen collection of surveiled individuals. (iv) the attempt to establish a predictive model to screen susceptibilities to zggj pill.

Eligibility criteria:
inclusion criteria: 1. individuals in accordance with indications for zggj pill, including osteoarthritis, and lumbar muscle strain; 2. the age range of 18 to 70 years； 3. individuals taking zggj pill over 2 weeks; 4. abnormalities of serum biochemistry achieving one of the criteria as follows: (i) alanine aminotransaminase (alt) or aspartate transaminase (ast) ≥2 folds of upper limit of normal (uln); (ii) total bilirubin (tbil) ≥ 2 uln; (iii) alkaline phosphatase (alp) ≥ 2 uln; 5. individuals can provide informed consent form. exclusion criteria: 1. individuals without indications for zggj pill; 2. inconformity with the zggj pill drug label; 3. individual taking zggj pill within 2 weeks; 4. individuals taking other hepatotoxic drugs combined with zggj pill, simultaneously; 5. inconformity with the diagnostic criteria for herb-induced liver injury (the guideline for diagnosis and treatment of herb-induced liver injury, rpgip-2016cn003）.

Keywords: drug-induced liver injury
a double blind placebo controlled trial evaluating rasagiline effects on cognition in parkinson's disease patients with mild cognitive impairment receiving dopaminergic therapy

Conditions: Parkinson's Disease

Summary: the present pilot study is designed to assess the extent to which rasagiline may improve cognition in parkinson's disease patients requiring dopaminergic therapy. the primary objective is to assess improvement in the montreal cognitive assessment (moca) in patients who have been on rasagiline at 1mg daily for twelve weeks. the secondary objective is to assess changes in the scopa-cog, fab, and updrs ii \& iii at the end of week 14.


Eligibility criteria:
inclusion criteria: * men and women aged 40 or older with idiopathic parkinson's disease on stable dopaminergic therapy for at least 1 month. the uk brain bank criteria will be used to establish the diagnosis of parkinson's disease. women must be post menopausal or agree to avoid pregnancy. modified hoehn \& yahr staging \< 3 and moca score must be greater than 21 but less than 28. geriatric depression scale (gds) is a sensitive and specific screen for depression in the parkinson's disease population. gds scores of \< 5 will be included in the study. exclusion criteria: * patients with secondary dementia, severe depression and atypical parkinson's syndromes or parkinson's plus will be excluded from the study. patients on acetylcholine esterase or nmda inhibitor medication will be excluded from the study. patients with history of brain surgery for parkinson's disease, stroke or significant head injury, active epilepsy will be excluded. patients on amantidine, neuroleptics, metoclopramide, alphamethyldopa within the last 6 months will be excluded. individuals using meperidine, and tramadol will be excluded. patients with congestive heart failure or myocardial infarction will also be excluded to avoid vascular dementia.

Keywords: parkinson's disease cognition rasagiline moca mild cognitive impairment in parkinson's disease
effects of physical activity, ambulatory blood pressure and calcium score on cardiovascular health in normal people

Conditions: Myocardial Infarction

Summary: a prospective cohort of relatively healthy individuals, using comprehensive clinical information, advanced imaging (including cardiac mri), cardiovascular exercise physiology, metabolomics and genetic analysis. these findings will be correlated with adverse clinical outcomes including death, stroke and myocardial infarction. in selected cases, follow-up imaging and biomarker samples will also be obtained. these studies will enable us to begin to address a critical gap in our knowledge as to how best to interpret the very large amount of cardiovascular tests done in singapore and how to better to predict outcomes and manage healthcare costs in our local populations

singheart sub-study will collect the following data types or perform the following investigations: 1. demographic and clinical characteristics data. 2. basic blood investigations. basic blood investigations include: fbc, crp, renal panel, random glucose, lft, fasting lipids, esr, crp, 3. perform a single baseline cardiac mri (already consented and obtained as part of the primary study). 4. ecg 5. calcium score 6. biobanking (whole blood, plasma and serum, already performed as part of the primary study) 7. exercise and physical activity tracker over two 1-week periods 8. ambulatory bp monitoring over two 24-48h periods

Eligibility criteria:
inclusion criteria: * men and women age 21-69 years exclusion criteria: 1. previous myocardial infarction (mi). this will include st-elevation mi (stemi) and non-st-elevation mi (nstemi) 2. known coronary artery disease - prior coronary revascularization 3. known documented peripheral arterial disease 4. previous stroke a. stroke is defined as new focal neurological deficit persisting more than 24hours21. 5. more than ongoing use of 2 or more anti-hypertensive agents 6. prior history of cancer (excludes pre-cancerous lesions) 7. expected life expectancy less than 1 year 8. known definite diabetes mellitus or on treatment for diabetes mellitus 9. known autoimmune disease or genetic disease 10. known endocrine disease on treatment 11. psychiatric illness 12. asthma or chronic lung disease requiring long term medications or oxygen 13. chronic infective disease, including tuberculosis, hepatitis b and c; and hiv 14. inability to comply with study protocol 15. any other acute or chronic medical or physical condition deemed by the investigator to affect study outcomes
an evaluation of the efficacy and safety of apalutamide as neoadjuvant endocrine therapy in high-risk and oligometastatic prostate cancer

Conditions: High-Risk and Oligometastatic Prostate Cancer

Summary: the neoadjuvant therapy with apalutamide can significantly improve the prognosis of patients with high-risk and oligometastatic prostate cancer, lower the rate of positive margins, reduce recurrence, and show high safety.


Eligibility criteria:
inclusion criteria: 1. adult males aged above 18 years old, no healthy volunteers included; 2. prostate cancer confirmed by pathological findings; 3. high risk based on risk assessment, or laboratory tests suggestive of oligometastasis; 4. agreement to undergo laparoscopic radical prostatectomy + pelvic lymphadenectomy; 5. ecog score of 0 - 1 6. agreement to undergo preoperative and postoperative endocrine therapy; 7. voluntary signing of an icf for the clinical trial exclusion criteria: 1. any other tumor disease requiring treatment; 2. any organ metastasis confirmed by imaging, such as liver and brain metastases, or the possibility of paralysis due to spinal cord metastasis; 3. a history of epilepsy or any condition that may lead to seizures; 4. severe liver or kidney dysfunction, severe cardiovascular or cerebrovascular diseases, and systemic immune system diseases.
effectiveness of a neoprene cmc joint orthosis

Conditions: CMC

Summary: patients will be gathered via convenience sample from a hand therapy clinic. they will be provided with a neoprene commercially available orthosis free of charge. baseline pain and function will be assessed using the vas and functional index of hand arthropathies. four weeks later, pain, function, and patient satisfaction with the device will be gathered using the quebec user evaluation of assistive technology questionnaire.

patients with the diagnosis of carpometacarpal osteoarthritis that are receiving hand therapy will be recruited for the study. baseline measurements will include usual pain over the past week, current pain, and worst pain experienced over the past week using the vas pain scale. hand function will be assessed using the functional index of hand arthropathies measure. the patients will be provided with a free neoprene hand orthosis (hely and weber cmc controller). they will be instructed to wear the device as needed for pain. after 1 month, the investigators will call the patient to assess pain, function, and satisfaction with the device using the quebec user evaluation of assistive technology questionnaire.

Eligibility criteria:
inclusion criteria: * cmc oa of either thumb with pain exclusion criteria: * cmc arthroplasty * recent surgery * dementia * no pain at cmc joint

Keywords: orthosis pain function
a study to assess the safety of adacel® vaccine

Conditions: Diphtheria; Tetanus; Pertussis

Summary: the objective of this study is to describe the safety of adacel® vaccination in adults subjects in vietnam. this study is conducted in accordance with vietnamese regulation in support to adacel® registration. primary objective: to monitor the adverse effects of the vaccine adacel® from day 0 to day 30 after immunization.

participants will receive a single dose of adacel® vaccine and will be followed closely during 30 minutes post-vaccination period; a home visit will be made daily during 7 days following vaccination in order to monitor safety. an additional visit will be conducted 30 days post-vaccination to collect safety information.

Eligibility criteria:
inclusion criteria : * male or female (not pregnant) from 18-45 years of age. * healthy, with no current illnesses. * have not been immunized against diphtheria, pertussis and tetanus in the past 5 years. * women of childbearing age will agree to use birth control during the study. * in good health, as verified by the following criteria: heart rate, blood pressure, temperature and health history. * able to understand and comply with requirements of the study. * a voluntary consent form is required before participating in the study. exclusion criteria : * history of allergy to any ingredient in the vaccine. * a positive pregnancy test (for women of childbearing age) or women who are breastfeeding. * compromised immune system due to treatment of a progressive disease. * currently on oral or injected steroids, inhaled high-dosage steroids or other immunodeficiency or toxic drugs. * history of taking immunoglobulin or other products during the 3 months prior to participating in the study. * received other vaccines during the 4 months prior to participating in the study. * has an acute or chronic condition that affects safety (including but not limited to: chronic liver disease, some kidney pathologies, progressive or unstabilized nerve disorders, diabetes and organ transplants). * experienced a severe adverse event after receiving adacel® vaccine. * history of acute illness with temperatures over 37.5ºc during the week before receiving the vaccine. * human immunodeficiency virus (hiv) infection. * history of alcohol or drug addiction during the past 5 years. * plans to travel outside of the study area between shots and visits. * history of guillain-barré syndrome.

Keywords: diphtheria tetanus pertussis adacel®
treatment of acne scars with fractional co2 laser versus radio-frequency microneedling

Conditions: Acne Scars - Mixed Atrophic and Hypertrophic

Summary: the study is a prospective, randomized, controlled, intra-person split-face trial with blinded evaluations. the objective is to compare efficacy and adverse effects of ablative fractional co2 laser resurfacing versus radio-frequency microneedling for treatment of atrophic acne scars in the facial area. two comparable areas with acne scars on each side of the face are treated. one area will be treated with fractional co2 laser and the other area with radio-frequency microneedling. outcome measures will be assessed by blinded investigators and included subjects at baseline before treatment and at follow-up visits 2-4 days and 1 and 3 months post-treatment. on-site assessment and oct will be performed at the time of the visits. oct scans will be offered to the subjects and are optional. clinical photos are used for documentation. 15 participants will be recruited. the participants will be recruited to enter the trial in the clinic by investigators at the department of dermatology, bispebjerg hospital, and must meet the inclusion criteria (at least 18 years of age, acne scars in the facial area, comparable atrophic acne scars on each side of the face, fitzpatrick skintype i-iii) to be eligible to enter the study. no personal remuneration will be awarded the investigators. none of the collaborators have any personal economic interest in the study. participants will not receive remuneration. all treatments are performed at the department of bispebjerg hospital and patients are covered by the hospital's patient insurance. the declaration of helsinki will be respected as well as the standards of good clinical research. respect for privacy as well as physically and mentally integrity of the participants will be maintained. the study will be performed in accordance with danish health care authorities.


Eligibility criteria:
inclusion criteria: * at least 18 years of age * acne scars in the facial area (predominantly rolling scars) * comparable atrophic acne scars on each side of the face * fitzpatrick skintype i-iii exclusion criteria: * pregnant or nursing women * treatment with isotretinoin within the last 6 months * current treatment with nsaid and prednisolone * known tendencies to produce hypertrophic scars or keloids * infection in the treatment area * considered unable to follow the study protocol, e.g. alcohol dependence syndrome

Keywords: fractional co2 laser radio-frequency microneedling